H.C. Wainwright raised the firm’s price target on Ardelyx to $13 from $11 and keeps a Buy rating on the shares post the Q4 report. The analyst projects U.S. Ibsrela annual net sales growth of 84% in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARDX:
- Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- After a Significant Stock Run, Market Awaits Ardelyx’s (NASDAQ:ARDX) Q4 Earnings
- Ardelyx call volume above normal and directionally bullish
- Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
- Ardelyx put volume heavy and directionally bearish
